Old Mission Investment Co LLC Acquires New Position in Johnson & Johnson $JNJ

Key Points

• Old Mission Investment Co. LLC purchased 15,094 Johnson & Johnson shares valued at approximately $3.83 million, making JNJ its 25th-largest holding and 0.8% of its portfolio.
• Institutional investors own 69.55% of JNJ, while company insiders sold $23.1 million worth of shares over the past three months.
• Johnson & Johnson exceeded quarterly earnings and revenue expectations and pays a $1.34 quarterly dividend, but shares trade at a relatively high P/E of 30.81 near their 12-month high, raising valuation and momentum concerns.

Old Mission Investment Co LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,094 shares of the company's stock, valued at approximately $3,833,000. Johnson & Johnson comprises about 0.8% of Old Mission Investment Co LLC's investment portfolio, making the stock its 25th largest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Montgomery Financial Services LLC purchased a new stake in shares of Johnson & Johnson during the second quarter valued at $43,000. Highland Investment Advisors LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth $79,000. Outlook Capital Management LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth about $28,000. Timbuktu Capital Management LLC acquired a new stake in Johnson & Johnson during the 2nd quarter worth about $264,000. Finally, TOP Private Wealth LLC. purchased a new stake in Johnson & Johnson during the 2nd quarter valued at about $265,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received CE Marking in Europe for ACUVUE OASYS MAX 2-Week reusable contact lenses, expanding its Vision Care product portfolio. The approval could support future sales, though its immediate financial impact is likely limited. Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
• Positive Sentiment: China approved Icotyde, J&J’s once-daily oral treatment for moderate-to-severe plaque psoriasis. The drug gives the company access to a large patient population and may attract patients who prefer an oral therapy to injectable alternatives, creating a potential growth catalyst. Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
• Positive Sentiment: Investor-focused coverage continues to highlight J&J as a Dividend Aristocrat that has maintained and increased its payout through past crises, supporting its appeal as a defensive income stock. The company also recently exceeded quarterly earnings and revenue expectations. 3 Top Dividend Aristocrats To Own Near All-Time Highs
• Neutral Sentiment: J&J is trading near its 12-month high after a strong advance, indicating sustained market confidence but also leaving less room for upside without additional earnings growth.
• Negative Sentiment: Analysts are questioning whether the rally is losing momentum. With shares valued at roughly 31 times earnings, profit-taking or valuation concerns could weigh on the stock despite the company’s defensive qualities and new growth opportunities. JNJ Stock: Is the Rally Running Out of Steam?

Insider Buying and Selling

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the business's stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 87,569 shares of company stock worth $23,064,544 in the last three months. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $265.91 on Monday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The company's fifty day moving average price is $263.03 and its 200 day moving average price is $245.93. The stock has a market capitalization of $640.82 billion, a P/E ratio of 30.81, a P/E/G ratio of 2.54 and a beta of 0.24. Johnson & Johnson has a 1 year low of $173.33 and a 1 year high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter last year, the business posted $2.77 earnings per share. The business's quarterly revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were issued a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio (DPR) is currently 62.11%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on JNJ shares. Bank of America increased their price target on shares of Johnson & Johnson from $254.00 to $263.00 and gave the stock a "neutral" rating in a report on Friday, July 10th. HSBC upped their price objective on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a report on Thursday. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an "overweight" rating in a research note on Thursday, July 16th. Freedom Capital raised shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. Finally, The Goldman Sachs Group restated a "buy" rating and set a $282.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $274.13.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.